[go: up one dir, main page]

WO2003106627A3 - CANCER-RELATED GENE GENE USED AS A TARGET FOR CHEMOTHERAPY - Google Patents

CANCER-RELATED GENE GENE USED AS A TARGET FOR CHEMOTHERAPY Download PDF

Info

Publication number
WO2003106627A3
WO2003106627A3 PCT/US2003/018533 US0318533W WO03106627A3 WO 2003106627 A3 WO2003106627 A3 WO 2003106627A3 US 0318533 W US0318533 W US 0318533W WO 03106627 A3 WO03106627 A3 WO 03106627A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
gene
methods
chemotherapy
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018533
Other languages
French (fr)
Other versions
WO2003106627A2 (en
Inventor
Krista Evans
Reinhard Ebner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clinical Data Inc
Original Assignee
Avalon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals Inc filed Critical Avalon Pharmaceuticals Inc
Priority to AU2003276643A priority Critical patent/AU2003276643A1/en
Publication of WO2003106627A2 publication Critical patent/WO2003106627A2/en
Publication of WO2003106627A3 publication Critical patent/WO2003106627A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Cette invention concerne de séquences de gènes liés au cancer et des séquences d'acides aminés dérivées ainsi que des méthodes destinées à analyser des agents anti-tumoraux potentiels en fonction de leur pouvoir de modulation de l'expression des gènes liés au cancer. L'invention concerne également des anticorps qui réagissent avec des polypeptides de l'invention ainsi que des méthodes d'utilisation de ces anticorps pour le traitement d'états cancéreux, par exemple pour le ciblage de cellules cancéreuses cibles in vivo, dans le but de leur administrer des agents thérapeutiques. Des méthodes de diagnostic à l'aide des séquences de gènes de l'invention sont également décrites.The present invention relates to cancer-related gene sequences and derived amino acid sequences, as well as methods for analyzing potential anti-tumor agents based on their ability to modulate the expression of cancer-related genes. The invention also relates to antibodies which react with polypeptides of the invention and to methods of using these antibodies for the treatment of cancerous conditions, for example for targeting target cancer cells in vivo, for the purpose of give them therapeutic agents. Methods of diagnosis using the gene sequences of the invention are also described.

PCT/US2003/018533 2002-06-13 2003-06-12 Cancer-linked gene as target for chemotherapy Ceased WO2003106627A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003276643A AU2003276643A1 (en) 2002-06-13 2003-06-12 Cancer-linked gene as target for chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38867302P 2002-06-13 2002-06-13
US60/388,673 2002-06-13

Publications (2)

Publication Number Publication Date
WO2003106627A2 WO2003106627A2 (en) 2003-12-24
WO2003106627A3 true WO2003106627A3 (en) 2004-06-24

Family

ID=29736512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018533 Ceased WO2003106627A2 (en) 2002-06-13 2003-06-12 Cancer-linked gene as target for chemotherapy

Country Status (2)

Country Link
AU (1) AU2003276643A1 (en)
WO (1) WO2003106627A2 (en)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAMBE M: "Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC)", IN VIVO, vol. 10, no. 3, 1996, pages 369 - 375, XP002976709 *
OZOREN N AND EL-DEIRY W: "Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis", EXPERIMENTAL CELL RESEARCH, vol. 281, no. 2, 2002, pages 175 - 181, XP002976708 *

Also Published As

Publication number Publication date
AU2003276643A1 (en) 2003-12-31
WO2003106627A2 (en) 2003-12-24
AU2003276643A8 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
WO2003105758A3 (en) CANCER-RELATED GENE USED AS A TARGET FOR CHEMOTHERAPY
WO2003104399A3 (en) Cancer-linked gene as target for chemotherapy
MA31862B1 (en) Antiseptic antibodies and their uses
TNSN05300A1 (en) Treatment with anti-vegf antibodies
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
MA43457A1 (en) Novel peptides, peptide combinations and carriers for use in the immunotherapeutic treatment of various cancers
ATE421589T1 (en) OPTICAL IMAGING SYSTEM FOR DISPLAYING GENE EXPRESSION OF THE ENTIRE BODY AND APPLICATIONS
WO2002086443A8 (en) Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
MA34738B1 (en) NEUTRALIZATION OF ANTI-CCL20 ANTIBODIES
MA38194A1 (en) Anti-ceacam5 antibodies and their uses
MA41237B1 (en) New peptides and peptide combinations for use in immunotherapy against hepatocellular carcinoma (chc) and other cancers
MA46022A (en) NEW PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST PROSTATE CANCER AND OTHER CANCERS
WO2003072125A8 (en) Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
ATE229073T1 (en) PROTEIN E25A, METHODS OF ITS PRODUCTION AND APPLICATION
TR200700740T2 (en) Nucleotide and protein sequences of Nogo genes and methods based on them
WO2006105439A3 (en) Susceptibility gene for myocardial infarction, stroke. and paod; methods of treatment
WO2003106627A3 (en) CANCER-RELATED GENE GENE USED AS A TARGET FOR CHEMOTHERAPY
Jiang et al. The expression of protease-activated receptors in esophageal carcinoma cells: The relationship between changes in gene expression and cell proliferation, apoptosis in vitro and growing ability in vivo
EP1496979A4 (en) ADENOVIRAL-PROTAMINE VECTOR COMPLEXES AND METHODS OF USE
WO2003104435A3 (en) CANCER-RELATED GENES AS CHEMOTHERAPY TARGETS
WO2003027633A3 (en) Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles
YU63702A (en) Novel antibody with specificity for colon cancer
WO2003104404A8 (en) CANCER-RELATED GENE AS A TARGET IN CHEMOTHERAPY
WO2003104436A3 (en) CANCER-RELATED GENE AS A TARGET FOR CHEMOTHERAPY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP